Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512225 | 0.97 | NPC1 (0.44) | PDE5AESR1PDE10AHIF1AKDM4E | |
| SCHEMBL5129883 | 0.92 | KDM4E (0.52) | ESR1HIF1AKDM4EMAPK1 | |
| SCHEMBL5129136 | 0.90 | ESR1 (0.49) | PDE5AESR1HIF1A | |
| SCHEMBL5122177 | 0.89 | ESR1 (0.45) | PDE5AESR1PDE10ABCDIN3D | |
| SCHEMBL5130300 | 0.86 | PDE5A (0.46) | PDE5APDE10AHIF1ABCDIN3D | |
| SCHEMBL5129707 | 0.86 | PDE5A (0.46) | PDE5APDE10AHIF1ABCDIN3D | |
| SCHEMBL5115035 | 0.85 | ESR1 (0.48) | PDE5AESR1BCDIN3D | |
| SCHEMBL5122543 | 0.83 | ALDH1A1 (0.52) | PDE5AESR1HIF1AKDM4EMAPK1 | |
| SCHEMBL5113662 | 0.83 | PDE5A (0.47) | PDE5APDE10AHIF1A | |
| SCHEMBL5778488 | 0.83 | MEN1 (0.51) | PDE5APDE10AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PDE5A 2002/4885ESR1 2256/4885PDE10A 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.